Matinas BioPharma Holdings (MTNB) Liabilities and Shareholders Equity (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $5.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $5.9 million, down 51.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.2 million (down 50.87% YoY), and the FY2025 annual result was $7.2 million, down 42.98% from the prior year.
• Liabilities and Shareholders Equity retreated to $5.9 million in Q1 2026 per MTNB's latest filing, from $7.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $55.8 million in Q1 2022 and troughed at $5.9 million in Q1 2026.
• A 5-year average of $26.5 million and a median of $24.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity retreated 22.9% in 2022, then tumbled 53.11% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $44.8 million in 2022, then slumped by 43.99% to $25.1 million in 2023, then tumbled by 49.65% to $12.6 million in 2024, then tumbled by 42.98% to $7.2 million in 2025, then declined by 18.51% to $5.9 million in 2026.
• Business Quant data shows MTNB's Liabilities and Shareholders Equity at $5.9 million in Q1 2026, $7.2 million in Q4 2025, and $9.7 million in Q3 2025.